Skip to content

Clinical trials

Phase 1/2 Lung Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Neoplasms Phase: Phase 1/2 Country / region: United States Clear all

210 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20013
20025
20039
20045
20055
20067
20078
200810
20097
20108
20112
20123
20132
20146
201511
20166
20179
201810
20199
20208
202115
20228
202313
20249
202511
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed90
Terminated46
Recruiting36
Active, not recruiting22
Unknown status7
Withdrawn6
Not yet recruiting2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center14
National Cancer Institute (NCI)12
Memorial Sloan Kettering Cancer Center9
Incyte Corporation5
University of California, Davis5
H. Lee Moffitt Cancer Center and Research Institute4
Massachusetts General Hospital4
Radiation Therapy Oncology Group4
Revolution Medicines, Inc.4
University of Alabama at Birmingham4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Neoplasms210
Carcinoma, Non-Small-Cell Lung128
Neoplasm Metastasis30
Neoplasms30
Breast Neoplasms26
Colorectal Neoplasms26
Head and Neck Neoplasms23
Colonic Neoplasms21
Pancreatic Neoplasms21
Melanoma20

Trials

Showing 1 to 25 of 210. Each trial links to its page on Pharma Observatory.

110 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.